Actualités réglementaires
12 sept. 2026•1 min de lecture
FDA Approves PROCHLORPERAZINE EDISYLATE Injection (ANDA212257)
The FDA has approved the ANDA212257 application for PROCHLORPERAZINE EDISYLATE injectable, manufactured by Somerset Therapeutics, for intramuscular and intravenous use.
Actualités réglementaires
31 août 2026•1 min de lecture
FDA ANDA089606: Watson Labs' PROCHLORPERAZINE EDISYLATE Injection Discontinued
The FDA’s ANDA089606 filing for Watson Labs’ prochlorperazine edisylate injectable is listed as discontinued, detailing route, dosage form, and active ingredient.